Merck & Co. Inc. (MRK) said on Friday that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex Inc. and Apotex Corp.
"While we are pleased with the court's ruling that the patent for Nasonex is valid, we are disappointed the court ruled that this patent would not be infringed by the Apotex product. We believe the patent for Nasonex in the United States is valid and would be infringed by the Apotex product," said Bruce N. Kuhlik, executive vice president and general counsel of Merck.
The company said it plans to review all of its options, including a likely appeal of the decision.
The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in Nasonex and which provides exclusivity for this form of mometasone until April 3, 2018.
Apotex is seeking U.S. Food and Drug Administration approval to sell a generic version of Nasonex.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.